Relay Therapeutics (RLAY) Q2 2026 earnings review
Clinical Progress Accelerates, Driving Both Cash Raise and Cash Burn
Relay Therapeutics continues to focus entirely on its clinical pipeline, with Q2 revenue remaining immaterial at $0.4 million. The core story is the aggressive advancement of its lead asset, zovegalisib, combined with a significantly fortified balance sheet. A $316 million equity raise in May pushed total cash to $911 million, securing funding into 2029. However, this clinical momentum is expensive: R&D expenses reversed their recent declining trend, accelerating 20% YoY to $76.5 million as Phase 3 trials and expansion cohorts ramp up, which drove the net loss down to $83.7 million.
🐂 Bull Case
The $316M equity raise pushes cash to $911M, eliminating near-term dilution risk and securing runway into 2029 to fund multiple Phase 3 trial catalysts.
The zovegalisib + atirmociclib triplet showed a strong 44% ORR in heavily pre-treated patients, validating the regimen and clearing the path for a Phase 3 trial in the lucrative frontline setting.
🐻 Bear Case
R&D expenses jumped 20% YoY, reversing the cost-saving narrative from late 2025 as the sheer volume of late-stage trials expands.
The pivotal Phase 3 1L trial initiation in early 2027 remains explicitly 'subject to regulatory feedback,' introducing significant timeline and execution risk.
⚖️ Verdict: ⚪
Neutral. The fortified balance sheet removes financing overhangs, and clinical data remains promising. However, accelerating cash burn and a long wait until the 2027 Phase 3 1L trial initiation require patience from investors.
Key Themes
Zovegalisib Triplet Validation and Pfizer Partnership
The selection of zovegalisib plus atirmociclib as the go-forward triplet regimen for 1L breast cancer is a major milestone. The company reported a 44% objective response rate (ORR) in heavily pre-treated (median 3L) patients at unoptimized doses, proving efficacy across both kinase and non-kinase PIK3CA mutations. Securing a clinical supply agreement with Pfizer for atirmociclib and palbociclib provides strategic validation while allowing Relay to retain full global rights.
Vascular Anomalies Expansion
The Phase 1/2 ReInspire trial delivered a 60% volumetric response at 12 weeks for adults and adolescents, with nearly all patients experiencing symptomatic improvement. Validated by this data, management is now opening expansion cohorts and escalating pediatric dosing (ages 6-11), systematically unlocking a market of approximately 170,000 patients per year in the U.S.
R&D Expense Trend Reverses Upward
After successfully reducing R&D costs in late 2024 and 2025 through strategic streamlining and the Elevar out-licensing, expenses are accelerating again. Q2 R&D jumped to $76.5M from $63.9M a year ago. As multiple Phase 3 trials (ReDiscover-2 and the upcoming 1L trial) and expansion cohorts activate, investors must monitor whether this new elevated run-rate is the baseline moving forward.
Phase 3 Timelines Subject to Regulatory Risk
While the clinical data is strong, the initiation of the Phase 3 1L trial is slated for early 2027 and is explicitly 'subject to regulatory feedback.' Any FDA requests for additional dosing data or trial design modifications could easily push this timeline further into 2027, delaying potential commercialization.
Other KPIs
Accelerating. Total cash position surged from $643.4 million in Q1 2026, driven by $316 million in gross proceeds from a May follow-on public offering. This fortress balance sheet fully funds the company through major upcoming data readouts.
Accelerating slightly from $13.6 million in Q2 2025 and $11.0 million in Q1 2026. Management attributed the YoY increase to higher legal expenses, which were only partially offset by lower employee stock compensation costs.
Guidance
Stable. The company reiterated its expectation that current cash will fund operations into 2029. The recent $316M equity raise significantly de-risked the balance sheet, ensuring they can absorb the higher R&D run rate without returning to the market in the near term.
Stable. Management committed to providing an enrollment update for the pivotal Phase 3 ReDiscover-2 trial in 2L breast cancer by the end of 2026, which will serve as the next major gauge of clinical execution.
Stable. Further data from the ReInspire trial and, crucially, a regulatory update will be provided by year-end, defining the registrational path forward in this indication.
Key Questions
Regulatory Feedback Hurdles
What specific regulatory feedback is required before initiating the Phase 3 1L breast cancer trial in early 2027, and what are the gating factors?
Normalized Cash Burn
Given the jump in Q2 R&D expenses to $76.5M, what is the anticipated normalized quarterly R&D cash burn as the Phase 3 trials fully ramp up?
Pfizer Agreement Economics
Does the clinical supply agreement with Pfizer for atirmociclib involve any milestone payments, royalties, or future exclusivity clauses?
G&A Expense Drivers
What drove the increase in G&A legal expenses this quarter, and is this an ongoing expected cost?